Results 111 to 120 of about 2,667 (188)

Eculizumab or ravulizumab treatment effect in people with neuromyelitis optica spectrum disorder: a plain language summary of three studies

Journal of Comparative Effectiveness Research
What is this summary about? Neuromyelitis optica spectrum disorder (NMOSD for short) is a rare autoimmune health condition, meaning that the body’s natural defense system (the immune system) attacks the body’s own tissues.
Alfredo Damasceno, Mariano Marrodan
doaj   +1 more source

Neuromyelitis Optica Spectrum Disorders – from pathophysiology to treatment [PDF]

Neuromyelitis optica spectrum disorders (NMOSD) are a group of autoimmune diseases characterized by severe, inflammatory attacks predominantly affecting the optic nerves and spinal cord and central nervous system.
Bochenek, Oliwia, Kałuża, Jessica Adriana, Konaszczuk, Adrian, Koper, Mateusz, Kozyra, Oliwia, Nowak, Aleksandra, Paluch, Katarzyna, Ratyna, Klaudia, Skarbek, Małgorzata, Szypuła, Zofia   +9 more
core   +1 more source

Neuromyelitis Optica Spectrum Disorder in a Pediatric Patient: Literature Review with Case Report [PDF]

Introduction: Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune astrocytopathy of the central nervous system (CNS) with secondary demyelination, often associated with the anti-aquaporin-4 (anti-AQP4) antibody.
de Almeida, Zenon Ferreira, de Freitas, Juliana Pastana Ramos, De Souza da Nóbrega, Rebeca   +2 more
core   +1 more source

Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria [PDF]

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disease of uncontrolled terminal complement activation leading to intravascular hemolysis, thrombotic events and increased morbidity and mortality.
Bartels, Marije, Baruchel, André, Buechner, Jochen, Chonat, Satheesh, Hicks, Eden, Kulagin, Alexander, Kulasekararaj, Austin G, Maschan, Alexey, Ogawa, Masayo, Punzalan, Rowena, Richards, Michael, Yu, Ji   +11 more
core  

VFC resolution update : meningococcal vaccines [PDF]

Mening-04-Whitlatch-508 ...

core  

The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference [PDF]

Uncontrolled complement activation can cause or contribute to glomerular injury in multiple kidney diseases. Although complement activation plays a causal role in atypical hemolytic uremic syndrome and C3 glomerulopathy, over the past decade, a rapidly ...
Barratt, Jonathan, Beck Jr, Laurence H, Cheung, Michael, Fakhouri, Fadi, Gale, Daniel P, Goicoechea de Jorge, Elena, Jadoul, Michel, King, Jennifer M, Mosca, Marta, Noris, Marina, Pickering, Matthew C, Smith, Richard JH, Susztak, Katalin, Thurman, Joshua M, Vivarelli, Marina, Winkelmayer, Wolfgang C   +15 more
core  

Optimizing Care in Patients with Paroxysmal Nocturnal Hemoglobinuria: Managing Suboptimal Response and Uncontrolled Disease. [PDF]

J Blood Med
Bienz M, Oliver M, Sperlich C, Patriquin CJ.   +3 more
europepmc   +1 more source

C3 mutation-associated atypical hemolytic uremic syndrome with severe renal dysfunction and hypertensive emergency successfully treated with ravulizumab and sacubitril/valsartan: a case report. [PDF]

BMC Nephrol
Yanagidani H, Maeoka Y, Yoshida M, Ueda M, Kumano M, Takahashi A, Okubo A, Kato N, Maruyama S, Masaki T.   +9 more
europepmc   +1 more source

Disease-modifying treatments in paroxysmal nocturnal hemoglobinuria: a systematic review of economic evaluations. [PDF]

Cost Eff Resour Alloc
Moradi S, Khajeamiri Y, Zandi S, Keramati M, Mohammadnezhad G.   +4 more
europepmc   +1 more source

Ravulizumab-Cwvz (Ultomiris®)

Oncology Times, 2019
openaire   +2 more sources